Two people join the cardiovascular and metabolic disease portfolio at the US research services firm
Crown Bioscience, a global drug discovery and development services company, has added Amar Thyagarajan and Sandeep Sinha to its team.
Thyagarajan has joined as Associate Director of product marketing and strategy.
He is responsible for the strategic and scientific marketing of CrownBio’s cardiovascular and metabolic disease (CVMD) portfolio.
Thyagarajan brings scientific and senior product management experience to the firm with genetically engineered models used in neuroscience and CVMD drug discovery and safety and toxicology studies.
He earned his doctorate in neuroscience at the State University of New York at Albany, followed by a postdoctoral fellowship at the Massachusetts Institute of Technology in neuroscience and chemical biology.
Sinha has joined the team as Scientific Director and is responsible for providing direction to CrownBio’s technical teams to build better partnerships with clients to accomplish successful CVMD programmes.
Prior to joining CrownBio, Sinha worked at Eli Lilly as a medical science liaison for diabetes and cardiovascular disease.
He received his doctorate in biochemistry from Aligarh Muslim University, India.
Sinha also served as a postdoctoral researcher at the University of Pittsburgh Medical Centre in the endocrine division and held research positions at several universities.